Effect of toll-like receptor 3 agonist poly I:C on intestinal mucosa and epithelial barrier function in mouse models of acute colitis

Hong-Wei Zhao, Yue-Hong Yue, Hua Han, Xi-Li Chen, Yong-Gang Lu, Ji-Min Zheng, Hong-Tao Hou, Xiao-Meng Lang, Li-Li He, Qi-Lu Hu, Zi-Qian Dun

Department of Gastroenterology, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China

Yue-Hong Yue, Department of Neurology, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China

Hua Han, Department of Obstetrics and Gynecology, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China

Xi-Li Chen, Research Center, The Fifth Hospital of Shijiazhuang, Shijiazhuang 050021, Hebei Province, China

Yong-Gang Lu, Department of Clinical Laboratory, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China

Xiao-Meng Lang, Department of Spleen and Stomach, Hebei Province Hospital of Traditional Chinese Medicine, Shijiazhuang 500011, Hebei Province, China

Li-Li He, Department of Gerontology, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China

Qi-Lu Hu, Department of Oncology, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China

Zi-Qian Dun, Department of General Internal Medicine, The Fifth Hospital of Shijiazhuang, Shijiazhuang 050021, Hebei Province, China

Author contributions: Zhao HW, Yue YH, Han H, Chen XL and Lu YG participated in study design, experiment performance, data interpretation and manuscript revision and coordination; Zheng JM, Hou HT and Lang XM contributed to experiment performance, data collection and manuscript drafting; He LL, Hu QL and Dun ZQ worked on experiment performance and manuscript revision; all authors contributed significantly to this work.

Supported by the Scientific Research Foundation of Health Department of Hebei Province, No. 20160483.

Institutional review board statement: This work was approved by the Institutional Review Board of Hebei General Hospital.

Institutional animal care and use committee statement: All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC, Approval ID: 107-038-3).

Conflict-of-interest statement: The authors declare no conflict of interest.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Correspondence to: Hong-Wei Zhao, MD, Department of Gastroenterology, Hebei General Hospital, No.348 Hepingxi Road, Shijiazhuang 050051, Hebei Province, China. hongweizhao788@163.com

Telephone: +86-13303039680

Fax: +86-311-85988449

Received: August 17, 2016

Peer-review started: August 19, 2016

First decision: September 6, 2016

Revised: September 26, 2016

Accepted: October 30, 2016
Abstract

AIM
To investigate potential effects of poly I:C on mucosal injury and epithelial barrier disruption in dextran sulfate sodium (DSS)-induced acute colitis.

METHODS
Thirty C57BL/6 mice were given either regular drinking water (control group) or 2% (w/v) DSS drinking water (model and poly I:C groups) ad libitum for 7 d. Poly I: C was administrated subcutaneously (20 µg/mouse) 2 h prior to DSS induction in mice of the poly I:C group. Severity of colitis was evaluated by disease activity index score, body weight, colon length, histology and myeloperoxidase (MPO) activity, as well as the production of proinflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin 17 (IL-17) and interferon-γ (IFN-γ). Intestinal permeability was analyzed by the fluorescein isothiocyanate labeled-dextran (FITC-D) method. Ultrastructural features of the colon tissue were observed under electron microscopy. Expressions of tight junction (TJ) proteins, including zo-1, occludin and claudin-1, were measured by immunohistochemistry/immunofluorescence, Western blot and real-time quantitative polymerase chain reaction (RT-qPCR).

RESULTS
DSS caused significant damage to the colon tissue in the model group. Administration of poly I:C dramatically protected against DSS-induced colitis, as demonstrated by less body weight loss, lower disease activity index score, longer colon length, colonic MPO activity, and improved macroscopic and histological scores. It also ameliorated DSS-induced ultrastructural changes of the colon epithelium, as observed under scanning electron microscopy, as well as FITC-D permeability. The mRNA and protein expressions of TJ protein, zo-1, occludin and claudin-1 were also found to be significantly enhanced in the poly I:C group, as determined by immunohistochemistry/immunofluorescence, Western blot and RT-qPCR. By contrast, poly I:C pretreatment markedly reversed the DSS-induced up-regulated expressions of the inflammatory cytokines TNF-α, IL-17 and IFN-γ.

CONCLUSION
Our study suggested that poly I:C may protect against DSS-induced colitis through maintaining integrity of the epithelial barrier and regulating innate immune responses, which may shed light on the therapeutic potential of poly I:C in human colitis.

Key words: Dextran sulfate sodium-induced acute colitis; Mucosal injury; Epithelial barrier disruption; Tight junction; Poly I:C

INTRODUCTION
Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are common chronic diseases that are characterized by abnormal mucosal immune response to luminal bacteria[1,2]. The innate and adaptive immune responses have been suggested to engage in the initiation of inflammation and relapse of disease activity, with increased intestinal levels of tumor necrosis factor-α (TNF-α), interleukin 17 (IL-17) and interferon-γ (IFN-γ)[3,4]. The increased intestinal inflammation may, in turn, lead to impaired mucosal barrier function and intestinal permeability, which allow subsequent translocation of microorganisms to the mucosal lymphatic tissue. The down-regulated expressions of junction complex proteins have been demonstrated in the intestinal mucosa of patients with IBD[5]. The impaired gut epithelial barrier function may cause persistent immune activation and, thereby, enhance inflammation of the intestinal mucosa[6].

Epithelial barrier function is determined by intestinal permeability, which is mainly maintained by tight junctions (TJs)[7]. As the most apical intercellular structure of the junctional complex in epithelial cells, TJs serve as the permeability barrier to paracellular transport of solutes[8,9]. Increased intestinal permeability has been reported to associate with the pathogenesis of IBD[10]. Therefore, maintenance of TJ and barrier function may be beneficial for patients with IBD[11-14].

Toll-like receptors (TLRs) are ancient microbial pattern recognition receptors that play an essential role in initiation of immune responses. Subcutaneous...
administration of poly I:C, a synthetic TLR3 agonist, has been reported to dramatically protect against dextran sulfate sodium (DSS)-induced acute colitis\[15\]. However, another study also indicated that abnormal activation of TLR3 signaling by poly I:C broke down the mucosal homeostasis and caused mucosal damage in the small intestine\[16\]. TLR3 signaling may be involved in the process of epithelial destruction and mucosal injury\[17\]. However, the potential effects of TLR3 activation by poly I:C on mucosal injury and epithelial barrier disruption in DSS-induced acute colitis have not been well investigated up to now. Therefore, the present study aimed to investigate the potential role of poly I:C administration on the intestinal mucosal barrier function and intestinal permeability in the mouse model of DSS-induced acute colitis.

**MATERIALS AND METHODS**

**Animals**

All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC, Approval ID: 107-038-3). Male C57BL/6 mice (8 wk, 18-22 g) were purchased from Vital River Laboratory Animal Technology Co. Ltd. (Beijing, China) [License No.: SCXK (Beijing) 2006-0009]. Animals were housed under standard conditions in a barrier facility, according to the protocols of IACUC and Hebei Medical University Vivarium (GB 14925-2001).

**Poly I:C reconstitution**

Poly I:C was prepared as described previously\[18\]. Briefly, poly I:C (GE Healthcare, Piscataway, NJ, United States) was dissolved in sterile phosphate-buffered saline (PBS) at a concentration of 2 mg/mL and heated at 50 °C until solubilization. The solution was then slowly cooled down to room temperature for proper annealing. The same lot of poly I:C was employed throughout the study.

**Acute colitis models**

Acute colitis was induced by DSS (40000-50000 MW; Sigma, St. Louis, MO, United States) as described in our previous report\[19\]. Briefly, 30 C57BL/6 mice were randomly assigned to three groups: control group, model group, and poly I:C group (n = 10 per group). Mice in the poly I:C group were administrated poly I:C subcutaneously (20 µg/mouse) in 100 µL PBS at 2 h prior to DSS treatment. Mice in the control and model groups were given normal saline. Animals were then given either regular drinking water (control group) or 2% (w/v) DSS drinking water (model and poly I:C groups) ad libitum for 7 d, and resumed on water for the remainder of the experiments.

**Disease activity assessment**

Rachmilewitz disease activity index (DAI) was assessed by an investigator blinded to the protocol and according to the well-established scoring system\[20\]. The data of body weight (BW), stool consistency and occult blood (OB) in the stool were recorded. Loss in BW was scored as: 0: no weight loss, 1: 1%-5% weight loss from baseline, 2: 5%-10%, 3: 10%-20%, and 4: more than 20% weight loss. Stool consistency was scored as: 0: well-formed pellets, 2: pasty and semi-formed stools that do not adhere to the anus, and 4: liquid stools that adhere to the anus. OB was scored as: 0: no blood, 2: positive hemoccult, and 4: gross bleeding. These scores were added together and divided by 3 to result in the DAI ranging from 0 (healthy) to 4 (maximal activity of colitis).

**Colonic injury and inflammation**

The entire colon (from the cecum to anus) was removed and the lengths were measured as an inflammation marker. The degree of colonic damage was examined macroscopically using a 0-4 scale\[19\]: 0: normal colon tissue; 1: minimal colon wall thickening without congestion; 2: moderate colon wall thickening with congestion; 3: moderate colon wall thickening, rigidity and congestion; and 4: marked colon wall thickening, rigidity, and congestion. The extent of tissue damage was assessed microscopically using a semi-quantitative scoring system\[21\]. In detail, the proximal colon was removed, fixed in 10% formalin and embedded in paraffin. The sections of 4 µm thickness were stained with hematoxylin and eosin (H&E) and scored using the following parameters: (1) severity of inflammation (0-3: none, slight, moderate, severe); (2) extent of injury (0-3: none, mucosal, mucosal and submucosal, transmural); and (3) crypt damage (0-4: none, basal 1/3 damaged, basal 2/3 damaged, only surface epithelium intact, entire crypt and epithelium lost). The total score was the sum of each parameter multiplying an equivalent reflecting the percentage of tissue involved (× 1: 0%-25%, × 2: 26%-50%, × 3: 51%-75%, × 4: 76%-100%).

**Myeloperoxidase activity assay**

Colons (100 mg wet weight) were isolated from each group and homogenized in 1 mL buffer (0.05% hexadecyltrimethylammonium bromide in 50 mmol/L phosphate buffer, pH 6.0). The resulting homogenates were centrifuged at 2000 g and 4 °C. The supernatants were transferred to a 96-well plate and incubated with 3 µL o-dianisidine hydrochloride (20 mg/mL) in 290 µL 50 mmol/L phosphate buffer and 3 µL H2O2 (20 mmol/L). The reaction was stopped by adding 3 µL sodium azide (30%). Light absorbance at 460 nm was read. MPO activity was determined by the curve obtained from the standard MPO\[22\].

**Immunohistochemistry/immunofluorescence**

For immunohistochemistry staining, the sections were...
boiled 10 min in 10 mmol/L citrate (pH 6.0) for antigen retrieval. The slides were then incubated with mouse monoclonal antibodies against claudin-1, occludin (Santa Cruz Biotechnology, Dallas, TX, United States), TNF-α, and IL-17 (Sigma), and rabbit polyclonal antibodies against zo-1 (1:150; Invitrogen, Carlsbad, CA, United States) and IFN-γ (1:300; Santa Cruz Biotechnology), followed by peroxidase-conjugated secondary antibodies (1:1500). The signals were visualized by a diaminobenzidine peroxidase substrate kit (Vector Laboratories, Burlingame, CA, United States). For immunofluorescence staining, the sections were incubated with mouse monoclonal antibodies against claudin-1 and occludin (1:200; Santa Cruz Biotechnology) and rabbit polyclonal antibody against zo-1 (1:150; Invitrogen), and subsequently with FITC- or Cy3-conjugated secondary antibodies. Images were captured under a Leica DMIRE2 confocal laser scanning microscope.

**In vivo permeability**

*In vivo* permeability assay was performed to assess barrier function by using a FITC-labeled dextran method. Briefly, food and water were withdrawn for 4 h and mice were then gavaged with permeability tracer (FITC-D, 60 mg/100 g body weight, MW 4000; Sigma). Serum was collected, and fluorescence intensity and FITC-dextran concentrations were determined. Permeability was calculated by linear regression of sample fluorescence.

**Scanning electron microscopy**

Specimens were fixed with 2.5% glutaraldehyde for 3 h at room temperature. The samples were then washed in acetone, critical point dried, and coated with gold for scanning electron microscopy (SEM).

**Real-time quantitative polymerase chain reaction**

Total RNA was extracted from colon tissues using Trizol reagent (Gibco-BRL Co., Grand Island, NY, United States) according to the manufacturer’s protocol and quantified using a UV spectrophotometer. Total RNA of 5 μg was used for first-strand cDNA synthesis. Real-time polymerase chain reaction (PCR) was performed with Quantitect™ SYBR® Green PCR Mastermix (Qiagen, Hilden, Germany) using 2 μL of cDNA template. The amplification program was 95°C for 5 min, 45 cycles of 95°C for 1 min and 60°C for 10 s. The primers used are summarized in Table 1. The relative quantitative analysis was performed by 2^−ΔΔCt method using Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as internal control.

**Western blot**

Protein concentration was determined by using Coomassie brilliant blue G250. Protein samples (100 μg) were resolved on 8% SDS polyacrylamide gel, electrotransferred to nitrocellulose membrane, and subsequently blocked in 5% skim milk in PBS. The membranes were incubated overnight at 4°C with rabbit polyclonal antibodies against zo-1 (1:100) and IFN-γ (1:200), mouse monoclonal antibodies against claudin-1 (1:200), occludin (1:200), TNF-α (1:200), and IL-17 (1:200), and rabbit anti-GAPDH monoclonal antibody (1:100). The secondary antibodies used were goat anti-rabbit or -mouse IgG (1:2000) and were incubated with membranes at room temperature for 2 h. Blots were visualized using enhanced chemiluminescence detection reagents (Santa Cruz Biotechnology) and quantified by Bandscan 5.0 software using GAPDH as the internal control.

**Statistical analysis**

Data were expressed as mean ± SD and analyzed with SPSS 13.0 software (SPSS, Inc., Chicago, IL, United States). Comparison between the groups was done by Student’s *t*-test. Comparison among the groups was conducted by one-way ANOVA analysis followed by LSD post-hoc test. Statistical significance was considered at *P* < 0.05.

### Table 1 Primers used for real-time quantitative polymerase chain reaction analysis

| Gene     | Primers                               | Length, bp |
|----------|---------------------------------------|------------|
| zo-1     | Forward 5'-TCATCCCAAAATAAGACAGAGC-3   | 198        |
|          | Reverse 5'-GAAGAACAAACCCCTTTCATAAGC-3' |            |
| Occludin | Forward 5'-CTTGGGCTGTCACCTGGCTTCT-3'  | 86         |
|          | Reverse 5'-CCTGGGCTGTCACCTGGCTTCT-3'  | 110        |
| Claudin-1| Forward 5'-GCTGGGTTTTACCTGGCTTCT-3'  | 161        |
| IL-17    | Reverse 5'-ATCCCTCTGTCATGGGAAG-3'     | 139        |
| IFN-γ    | Reverse 5'-TTTCTCCACTATCTGACCCTT-3'   | 169        |
| TNF-α    | Reverse 5'-GGTTCGCTCCCCACTCTC-3'      | 263        |
| GAPDH    | Forward 5'-ATGCACCGACGATTCCC-3'       |            |

IL-17: Interleukin 17; IFN-γ: Interferon-γ; TNF-α: Tumor necrosis factor-α; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase.
RESULTS

Poly I:C ameliorated DSS-induced acute colitis
DSS caused significant damage to the colon tissue, with the gut inflammation and weight loss noted in the model group during 1 to 8 d observation. Administration of poly I:C partially reversed the DSS-induced effects, with less BW loss (Figure 1A). The general condition of mice was evaluated using a DAI that scored the extent of BW loss, stool consistency, and OB. As shown in Figure 1B, DAI was significantly enhanced in the DSS-induced model group, and this effect was partially alleviated by poly I:C. The colitic parameters were further quantified after monitoring clinical development of colitis for 8 d. As shown in Figure 1C and D, the colon length in the model group was significantly shorter than that of the control group (P < 0.01), while pretreatment with poly I:C significantly reduced the DSS-induced colon shortening (P < 0.01). Macroscopically, mice in the model group had significantly higher inflammation score than those in the control and poly I:C groups (P < 0.01; Figure 1E). Histopathological analysis in the model group showed extensive ulceration of the epithelial layer, edema and crypt damage of the bowel wall. The fibrosis of muscularis mucosae and infiltration of granulocytes and mononuclear cells into the mucosa were also observed (Figure 1G). The histology score was significantly higher in the model group than that in the control group (P < 0.01). In contrast, poly I:C pretreatment obviously reversed this DSS-induced effect, with comparatively lower histology score noted in the poly I:C group (Figure 1H).

Poly I:C attenuated DSS-induced paracellular permeability
MPO activity is shown in Figure 2A. Mice in the model group showed significantly higher MPO activity than that in the control group (P < 0.01), while the data were significantly lower in mice of the poly I:C group (P < 0.01). To investigate the effect of poly I:C on paracellular permeability, intestinal permeability to FITC-D was determined. The results showed the increased permeability to 4-kDa FITC-D induced by colitis, while mice in the poly I:C group showed a lower intestinal permeability than that of the model group (P < 0.01; Figure 2B). SEM observations of the colonic mucosa showed severe mucosal loss with typical histological inflammation feature in the mice of the model group (Figure 2C). Besides, enterocytes in the mice of the model group showed less glyocalyx and more irregular surface than the control group. By contrast, pretreatment with poly I:C obviously ameliorated the DSS-induced ultrastructural changes, with few histological lesions observed.

Poly I:C inhibited DSS-induced colonic inflammation
To determine the anti-inflammatory effect of poly I:C on the DSS-induced colitis, expressions of inflammatory markers, including IL-17, TNF-α and IFN-γ, were analyzed by real-time quantitative polymerase chain reaction (RT-qPCR), immunohistochemistry, and Western blot. RT-qPCR analysis showed the up-regulated expressions of IL-17, TNF-α and IFN-γ in the mice of the model group, while pretreatment with poly I:C caused the down-regulated expression of these inflammatory cytokines (P < 0.01; Figure 3A). These results were further confirmed by immunohistochemistry and Western blot analysis, which indicated the enhanced expressions of IL-17, TNF-α and IFN-γ in the model group. By contrast, poly I:C pretreatment markedly reversed the DSS-induced up-regulation of the inflammatory cytokines (P < 0.01; Figure 3B and C).

DISCUSSION

Poly I:C prevented DSS-induced TJ disruption
To investigate the protective effect of poly I:C on the DSS-induced disruption of TJ, the expression of TJ markers, including zo-1, occludin and claudin-1, were analyzed by immunohistochemistry, immunofluorescence, RT-qPCR, and Western blot. Immunohistochemistry and immunofluorescence assays showed that, in the control group, TJ proteins were expressed in the cytomembrane of epithelial cells, and most commonly in the spinous and granular layers, whereas expressions of these TJ proteins in the model group were significantly decreased. In the poly I:C group, however, the increased expression of TJ proteins were observed in the both cytomembrane and cytoplasm of spinous and granular layers in the mucosa (Figure 4A and B). Further quantitative analysis of TJ protein expressions by RT-qPCR and Western blot confirmed the down-regulated expression of TJ proteins in the model group when compared with the control group. Meanwhile, this effect was compromised by poly I:C pretreatment, with the comparatively higher expressed TJ markers (P < 0.01; Figure 4C and D).

Poly I:C is a ligand for TLR3 that is involved in the innate immune response to viral infection[24]. Administration of poly I:C in wild-type mice has been reported to dramatically protect against DSS-induced colitis, as demonstrated by parameter analysis of body weight, rectal bleeding, colonic MPO activity, histopathology, and etc[15]. However, another study also indicated that abnormal activation of TLR3 signaling by poly I:C broke down the mucosal homeostasis and caused intestinal mucosal damage[16]. Therefore, the potential role of poly I:C in the mucosal injury and epithelial barrier disruption was further investigated in DSS-induced acute colitis. The findings of our study showed that poly I:C administration obviously ameliorated the clinical symptoms of DSS-induced acute colitis, as demonstrated by less BW loss, lower DAI score, longer colon length, and
Figure 1  Effect of poly I:C administration on dextran sulfate sodium-induced acute colitis. A: The percentage of body weight change assessed daily during 1 to 8 d observation; B: Change in the disease activity index that was comprised of body weight loss, stool consistency and occult blood; C: Representative photographs of colon obtained after monitoring clinical development of colitis for 8 d; D: Quantitative analysis of the length of the colon; E: Macroscopic score inflammation assessed; F: Histological scores of the colon tissues; G: Representative photographs of HE staining of colon tissues (Magnifications, × 200). Data are expressed as mean ± SD. *P < 0.01 vs control group; †P < 0.01 vs model group.
improved macroscopic and histological scores. These results were consistent with the findings reported by Vijay-Kumar et al.[15], which indicated the protective effect of TLR3 activation by poly I:C on DSS-induced acute colitis.

The intestinal barrier has been reported to be defective and associated with paracellular leakiness in inflammatory bowel conditions of UC[25]. TJ protein is the most apical component responsible for restricting paracellular permeability of the intestinal mucosa[26]. Poly I:C administration has been demonstrated to protect against DSS-induced acute colitis. However, abnormal activation of TLR3 signaling by poly I:C has been reported to break down the mucosal homeostasis and cause mucosal damage in the small intestine[16]. TLR3 signaling may be involved in the process of epithelial destruction and mucosal injury[17].

These conflicting results urged us to study the effect of poly I:C on paracellular permeability and epithelial barrier function in DSS-induced acute colitis models.

Corroborating the findings of our previous study[19] and the study of others[15], the present study showed increased paracellular permeability and disrupted TJ induced by DSS, as assessed by FITC-D level, ultrastructure of colon mucosa, and expression and distribution of TJ proteins (zo-1, occludin, and claudin-1). However, unlike the results of our study, another study also indicated that colonic paracellular permeability increase...
was not significantly altered by DSS exposure, and DSS mice only showed a trend of increased expressions of claudin-1 and claudin-2\cite{27}. This variation may be partially explained by the different methods used to establish the acute colitis models.

The potential effects of poly I: C administration were then analyzed. Paracellular permeability and TJ were found to be significantly ameliorated when mice were pretreated with poly I: C, as demonstrated by decreased FITC-D permeability, ameliorated ultrastructural changes, and enhanced expression of TJ proteins at the both mRNA and protein levels. The direct effect

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure3.png}
\caption{Effect of poly I: C on the expressions of inflammatory markers. A: Representative photographs of immunohistochemistry staining of IL-17, TNF-\(\alpha\) and IFN-\(\gamma\) in colon tissues (Magnifications, \(\times\) 200); B: Expressions of IL-17, TNF-\(\alpha\) and IFN-\(\gamma\) at the mRNA level, as analyzed by RT-qPCR; C: Protein expressions of IL-17, TNF-\(\alpha\) and IFN-\(\gamma\) as analyzed by Western Blot. Data are expressed as mean \(\pm\) SD. \(^bP<0.01\) vs control group; \(^dP<0.01\) vs model group. RT-qPCR: Real-time quantitative polymerase chain reaction; IL-17: Interleukin-17; TNF-\(\alpha\): Tumor necrosis factor-\(\alpha\); IFN-\(\gamma\): Interferon-\(\gamma\).}
\end{figure}
of poly I:C on intestinal barrier function has been investigated in vitro by Moyano-Porcile et al.\(^{[28]}\), and indicated that acute exposure of rat ileum and colon tissues to poly I:C reduced colon permeability to macromolecules, while increasing ileum permeability to micromolecules. Intraperitoneal injection of poly I:C has been reported to cause severe mucosal injury of the small intestine, along with the increased levels of IL-15\(^{[16]}\).

Activation of TLR-3 seems to cause adverse effects on various epithelial barriers, like the blood-brain barrier and nasal epithelial barriers\(^{[29,30]}\). However, to the best of our knowledge, this study is the first to investigate the effect of poly I:C on intestinal barrier function in DSS-induced acute colitis. Our results suggested that administration of poly I:C in DSS-induced colitis models may help to maintain the integrity of ultrastructure of the epithelial mucosa and junction complex, and therefore decrease paracellular permeability and recover epithelial barrier function.

TJ is known to be the rate-limiting step in transepithelial transport and the principal determinant of inte-
Stomal permeability[21]. Increased intestinal permeability and disrupted TJ may cause bowel inflammation[32,33]. TNF-α is a proinflammatory cytokine that has long been established as a key player in the pathogenesis of IBD diseases. Proinflammatory cytokines such as TNF-α and IFN-γ have also been linked to the increased paracellular permeability[34-36]. Ligation of TLR3 by poly I:C has been suggested to be effective in IBD-associated gut inflammation[14,15]. This may shed light on the barrier protective effect of poly I:C as a likely candidate mechanism that contributes to therapeutic efficacy in IBD diseases. Therefore, the expressions of proinflammatory cytokines (IL-17, TNF-α, and IFN-γ) in colon epithelium were analyzed. Consistent with the result of the above mentioned study, our study showed the increased production of proinflammatory cytokines TNF-α, IL-17 and IFN-γ in mice of the DSS-induced model group. However, mice pretreated with poly I:C showed ameliorated DSS-induced high-expression of these proinflammatory cytokines. These results suggested that poly I:C may ameliorate inflammation in the colitis models.

In conclusion, the findings of our study showed evidence to suggest that poly I:C may protect against DSS-induced acute colitis through maintaining integrity and regulating the innate immune responses, which may shed light on the therapeutic potential of poly I:C in clinical colitis.

**COMMENTS**

**Background**

The toll-like receptor 3 (TLR3) agonist poly I:C has been reported to protect against acute colitis.

**Research frontiers**

TLR3 signaling may be involved in the process of epithelial destruction and mucosal injury. However, the potential effects of TLR3 activation by poly I:C on the mucosal injury and epithelial barrier disruption in dextran sulfate sodium (DSS)-induced acute colitis have not been well investigated up to now.

**Innovations and breakthroughs**

The potential roles of poly I:C administration in intestinal mucosal barrier function and intestinal permeability were investigated in a mouse model of DSS-induced acute colitis. Poly I:C administration dramatically protected against DSS-induced colitis. It also ameliorated DSS-induced ultrastructural changes of the colon epithelium, as well as fluorescence isothiocyanate labeled-dextran permeability and tight junction protein expressions.

**Applications**

Poly I:C may protect against DSS-induced colitis through maintaining integrity of the epithelial barrier and regulating innate immune responses, which may shed light on the therapeutic potential of poly I:C in human colitis.

**Peer-review**

In general, the present work is well done and the paper describes results of interest for the inflammatory bowel disease research community working with animal models of gut inflammation.

**REFERENCES**

1 Song-Zhao GX, Maloy KJ. Experimental mouse models of T cell-dependent inflammatory bowel disease. *Methods Mol Biol* 2014; 1193: 199-211 [PMID: 25151008 DOI: 10.1007/978-1-4939-1212-418]

2 Geen D, Harusato A, Flannigan K, Denning TL. Harnessing regulatory T cells for the treatment of inflammatory bowel disease. *Inflamm Bowel Dis* 2015; 21: 1409-1418 [PMID: 25793328 DOI: 10.1097/MIB.0000000000000343]

3 Guéry L, Hugues S. Th17 Cell Plasticity and Functions in Cancer Immunity. *Biomol Res Int* 2015; 2015: 314620 [PMID: 26583099 DOI: 10.1155/2015/314620]

4 Park JS, Yi TG, Park JM, Han YM, Kim JH, Shin DH, Tak SJ, Lee K, Lee YS, Jeon MS, Hahn KB, Song SU, Park SH. Therapeutic effects of mouse bone marrow-derived clonal mesenchymal stem cells in a mouse model of inflammatory bowel disease. *J Clin Biochem Nutr* 2015; 57: 192-203 [PMID: 26566304 DOI: 10.3164/jcnb.15-56]

5 Aherne CM, Saeedi B, Collins CB, Masterson JC, McNamere EN, Perrenoud L, Rapp CR, Curtis VF, Bayless A, Fletcher A, Glover LE, Evans CM, Jedlicka P, Furuta GT, de Zoenen EF, Colgan SP, Eltzschig HK. Epithelial-specific A2B adenosine receptor signaling protects the colonic epithelial barrier during acute colitis. *Mucosal Immunol* 2015; 8: 1324-1338 [PMID: 25850656 DOI: 10.1038/mi.2015.22]

6 Luo K, Cao SS. Endoplasmic reticulum stress in intestinal epithelial cell function and inflammatory bowel disease. *Gastroenterol Res Pract* 2015; 2015: 328791 [PMID: 25755688 DOI: 10.1155/2015/328791]

7 Schulze JD, Bojarski C, Zeissig S, Heller F, Gitter AH, Fromm M. Disrupted barrier function through epithelial cell apoptosis. *Ann N Y Acad Sci* 2006; 1072: 288-299 [PMID: 17057208 DOI: 10.1196/annals.1326.027]

8 Borkowski AW, Kuo IH, Bernard JJ, Yoshida T, Williams MR, Hung NJ, Yu BD, Beck LA, Gallo RL. Toll-like receptor 3 activation is required for normal skin barrier repair following UV damage. *J Invest Dermatol* 2015; 135: 569-578 [PMID: 25118157 DOI: 10.1038/jid.2014.354]

9 Clark PR, Kim RK, Pober JS, Kluger MS. Tumor necrosis factor disrupts claudin-5 endothelial tight junction barriers in two distinct NF-κB-dependent phases. *PLOS One* 2015; 10: e0120075 [PMID: 25816133 DOI: 10.1371/journal.pone.0120075]

10 Luijsint AC, Bennett A, Nishio H, Hilgarth R, McCaill I, Nusrat A, Parkos CL. CLMP Expression is Increased in the Intestinal Epithelium Under Inflammatory Conditions and Regulates Intercellular Adhesion, Proliferation and Migration. *FASEB J* 2015; 29: 282-289 [DOI: 10.1096/fj.15-138066]

11 Mielke I, Preudet A, Belz G, Putoczki T. Conflocal laser endomicroscopy to monitor the colonic mucosa of mice. *J Immunol Methods* 2015; 421: 81-88 [PMID: 25960174 DOI: 10.1016/j.jim.2015.04.012]

12 Hummel S, Veltman K, Cichon C, Sonnenborn U, Schmidt MA. Differential targeting of the E-Cadherin/p-Catenin complex by gram-positive probiotic lactobacilli improves epithelial barrier function. *Appl Environ Microbiol* 2012; 78: 1140-1147 [PMID: 22179242 DOI: 10.1128/AEM.06983-11]

13 McMbl BL, Gibson AJ, Overman EL, Stahl C, Moeser AJ. Early weaning stress in pigs impairs mucosal immune responses to enterotoxigenic E. coli challenge and exacerbates intestinal injury and clinical disease. *PLOS One* 2013; 8: e59838 [PMID: 23637741 DOI: 10.1371/journal.pone.0059838]

14 Salvo Romero E, Alonso Cotoner C, Pardo Camacho C, Casado Bedmar M, Vicario M. The intestinal barrier function and its involvement in digestive disease. *Rev Esp Enferm Dig* 2015; 107: 686-696 [PMID: 26541659 DOI: 10.17232/reed.2015.3846/2015]

15 Vijay-Kumar M, Wu H, Aitken J, Kolachala VL, Neish AS, Siriraman SV, Gewirtz AT. Activation of toll-like receptor 3 protects against DSS-induced acute colitis. *Inflamm Bowel Dis* 2007; 13: 856-864 [PMID: 17393379 DOI: 10.1002/ibd.20142]

16 Zhou R, Wei H, Sun R, Tian Z. Recognition of double-stranded RNA by TLR3 induces severe small intestinal injury in mice. *J Immunol* 2007; 178: 4548-4556 [PMID: 17372013 DOI: 10.4049/jimmunol.178.7.4548]
Zhao HW et al. Poly I:C and intestinal barrier function.

P- Reviewer: Gazouli M, Sandvik AK  S- Editor: Gong ZM  L- Editor: Filipedia  E- Editor: Liu WX
